JIN-A02
- Generic Name
- JIN-A02
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Phase 1
Recruiting
- Conditions
- EGFR Mutant Advanced Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- J Ints Bio
- Target Recruit Count
- 150
- Registration Number
- NCT05394831
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, University of California Irvine Healthcare, Orange, California, United States
🇰🇷Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
🇰🇷National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath